William Blair Investment Management LLC Trims Holdings in Hims & Hers Health, Inc. $HIMS

William Blair Investment Management LLC trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 40.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 222,487 shares of the company’s stock after selling 148,212 shares during the quarter. William Blair Investment Management LLC owned about 0.10% of Hims & Hers Health worth $11,091,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the first quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Hims & Hers Health during the first quarter valued at approximately $41,000. Larson Financial Group LLC raised its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after acquiring an additional 458 shares in the last quarter. Webster Bank N. A. raised its position in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock valued at $45,000 after acquiring an additional 630 shares in the last quarter. Finally, Tsfg LLC purchased a new position in Hims & Hers Health during the first quarter valued at approximately $46,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 3.3%

Shares of HIMS opened at $51.40 on Tuesday. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12 month low of $18.33 and a 12 month high of $72.98. The stock’s 50 day moving average is $51.04 and its two-hundred day moving average is $49.21. The firm has a market cap of $11.62 billion, a P/E ratio of 64.25, a PEG ratio of 3.39 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on HIMS shares. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $38.92.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 900 shares of Hims & Hers Health stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $58.25, for a total value of $52,425.00. Following the sale, the insider directly owned 291,439 shares of the company’s stock, valued at $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Soleil Boughton sold 2,637 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $54.38, for a total value of $143,400.06. Following the completion of the sale, the insider directly owned 161,130 shares in the company, valued at $8,762,249.40. This represents a 1.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,448,056 shares of company stock valued at $75,139,240. Insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.